Zejula

Zejula (niraparib) is an oral prescription medication used for certain types of ovarian, fallopian tube, or primary peritoneal cancer. It belongs to a class of drugs known as PARP inhibitors, designed to help slow cancer progression. This medication is taken once daily in capsule form. Always follow your healthcare provider's guidance when using Zejula.

Zejula (niraparib) is primarily used for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. It is also indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have responded to first-line platinum-based chemotherapy. Zejula is designed to help delay cancer progression in these patients.

Zejula (niraparib) works by helping to prevent cancer cells from repairing their DNA, which may slow or stop their growth. Patients may experience side effects such as nausea, fatigue, or changes in blood cell counts. Regular monitoring is important to manage any potential effects. Individual responses to the medication can vary.

Zejula should be taken exactly as prescribed by a healthcare provider. It is important to discuss your full medical history, including any blood disorders or liver problems, before starting treatment. Patients should report any unusual symptoms, such as severe fatigue or signs of infection, to their doctor promptly. Keep this medication out of reach of children.

Zejula may interact with other medications, including certain antidepressants, antifungals, and blood thinners. Avoid grapefruit products while taking this medication, as they may affect how it works. Always inform your healthcare provider about all prescription, over-the-counter, and herbal products you are using. Regular blood tests may be required to monitor for interactions.